drugset / Trial / NCT01238783

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

NCT01238783

Phase 2 Withdrawn Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess safety and efficacy of AL-15469A 0.5% /AL-6515 0.3% Ophthalmic Suspension for treatment of bacterial conjunctivitis

Timeline

Start
2011-01
Primary completion
2011-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 0.5 % Topical
Subject Nepafenac Other / unclassified 0.3 % Topical